{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:56:08Z","timestamp":1787500568915,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1212\/01.con.0000464178.81957.18","type":"journal-article","created":{"date-parts":[[2015,4,3]],"date-time":"2015-04-03T12:05:26Z","timestamp":1428062726000},"page":"415-428","source":"Crossref","is-referenced-by-count":12,"title":["Nervous System Metastases From Systemic Cancer"],"prefix":"10.1212","volume":"21","author":[{"given":"Eudocia Q.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"crossref","unstructured":"Nayak L Lee EQ Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2012; 14 (1): 48\u201354. doi:10.1007\/s11912-011-0203-y.","DOI":"10.1007\/s11912-011-0203-y"},{"key":"e_1_3_1_4_2","doi-asserted-by":"crossref","unstructured":"Sperduto PW Kased N Roberge D et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30 (4): 419\u2013425. doi:10.1200\/JCO.2011.38.0527.","DOI":"10.1200\/JCO.2011.38.0527"},{"key":"e_1_3_1_5_2","doi-asserted-by":"crossref","unstructured":"Glantz MJ Cole BF Forsyth PA et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54 (10): 1886\u20131893. doi:10.1212\/WNL.54.10.1886.","DOI":"10.1212\/WNL.54.10.1886"},{"key":"e_1_3_1_6_2","doi-asserted-by":"crossref","unstructured":"Mills SJ Thompson G Jackson A. Advanced magnetic resonance imaging biomarkers of cerebral metastases. Cancer Imaging 2012; 12: 245\u2013252. doi:10.1102\/1470-7330.2012.0012.","DOI":"10.1102\/1470-7330.2012.0012"},{"key":"e_1_3_1_7_2","doi-asserted-by":"crossref","unstructured":"Lu-Emerson C Eichler AF. Brain metastases. Continuum (Minneap Minn) 2012; 18 (2): 295\u2013311. doi:10.1212\/01.CON.0000413659.12304.a6.","DOI":"10.1212\/01.CON.0000413659.12304.a6"},{"key":"e_1_3_1_9_2","doi-asserted-by":"crossref","unstructured":"Tsao MN Khuntia D Mehta MP. Brain metastases: what\u2019s new with an old problem? Curr Opin Support Palliat Care 2012; 6 (1): 85\u201390. doi:10.1097\/SPC.0b013e32834de714.","DOI":"10.1097\/SPC.0b013e32834de714"},{"key":"e_1_3_1_10_2","doi-asserted-by":"crossref","unstructured":"Patchell RA Tibbs PA Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322 (8): 494\u2013500. doi:1056\/NEJM199002223220802.","DOI":"10.1056\/NEJM199002223220802"},{"key":"e_1_3_1_11_2","doi-asserted-by":"crossref","unstructured":"Vecht CJ Haaxma-Reiche H Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33 (6): 583\u2013590.","DOI":"10.1002\/ana.410330605"},{"key":"e_1_3_1_12_2","doi-asserted-by":"crossref","unstructured":"Andrews DW Scott CB Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004; 363 (9422): 1665\u20131672. doi:10.1016\/S0140-6736(04)16250-8.","DOI":"10.1016\/S0140-6736(04)16250-8"},{"key":"e_1_3_1_14_2","doi-asserted-by":"crossref","unstructured":"Kocher M Soffietti R Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011; 29 (2): 134\u2013141. doi:10.1200\/JCO.2010.30.1655.","DOI":"10.1200\/JCO.2010.30.1655"},{"key":"e_1_3_1_15_2","doi-asserted-by":"crossref","unstructured":"Brown PD Pugh S Laack NN et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized double-blind placebo-controlled trial. Neuro Oncol 2013; 15 (10): 1429\u20131437. doi:10.1093\/neuonc\/not114.","DOI":"10.1093\/neuonc\/not114"},{"key":"e_1_3_1_17_2","doi-asserted-by":"crossref","unstructured":"Dietrich J Monje M Wefel J et al. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008; 13 (12): 1285\u20131295. doi:10.1634\/theoncologist.2008-0130.","DOI":"10.1634\/theoncologist.2008-0130"},{"key":"e_1_3_1_18_2","doi-asserted-by":"crossref","unstructured":"Bachelot T Romieu G Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013; 14 (1): 64\u201371. doi:10.1016\/S1470-2045(12)70432-1.","DOI":"10.1016\/S1470-2045(12)70432-1"},{"key":"e_1_3_1_19_2","doi-asserted-by":"crossref","unstructured":"Lin NU Eierman W Greil R et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011; 105 (3): 613\u2013620. doi:10.1007\/s11060-011-0629-y.","DOI":"10.1007\/s11060-011-0629-y"},{"key":"e_1_3_1_20_2","doi-asserted-by":"crossref","unstructured":"Freedman RA Bullitt E Sun L et al. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer 2011; 11 (6): 376\u2013383. doi:10.1016\/j.clbc.2011.03.024.","DOI":"10.1016\/j.clbc.2011.03.024"},{"key":"e_1_3_1_21_2","doi-asserted-by":"crossref","unstructured":"Long GV Trefzer U Davies MA et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre open-label phase 2 trial. Lancet Oncol 2012; 13 (11): 1087\u20131095. doi:10.1016\/S1470-2045(12)70431-X.","DOI":"10.1016\/S1470-2045(12)70431-X"},{"key":"e_1_3_1_22_2","doi-asserted-by":"crossref","unstructured":"Margolin K Ernstoff MS Hamid O et al. Ipilimumab in patients with melanoma and brain metastases: an open-label phase 2 trial. Lancet Oncol 2012; 13 (5): 459\u2013465. doi:10.1016\/S1470-2045(12)70090-6.","DOI":"10.1016\/S1470-2045(12)70090-6"},{"key":"e_1_3_1_23_2","doi-asserted-by":"crossref","unstructured":"Soffietti R Trevisan E Ruda R. Targeted therapy in brain metastasis. Curr Opin Oncol 2012; 24 (6): 679\u2013686. doi:10.1097\/CCO.0b013e3283571a1c.","DOI":"10.1097\/CCO.0b013e3283571a1c"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Clarke JL. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn) 2012; 18 (2): 328\u2013342. doi:10.1212\/01.CON.0000413661.58045.e7.","DOI":"10.1212\/01.CON.0000413661.58045.e7"},{"key":"e_1_3_1_25_2","doi-asserted-by":"crossref","unstructured":"Chamberlain MC. Neoplastic meningitis. J Clin Oncol 2005; 23 (15): 3605\u20133613. doi:10.1200\/JCO.2005.01.131.","DOI":"10.1200\/JCO.2005.01.131"},{"key":"e_1_3_1_26_2","doi-asserted-by":"crossref","unstructured":"Chamberlain M Soffietti R Raizer J et al. Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol 2014; 16 (9): 1176\u20131185. doi:10.1093\/neuonc\/nou089.","DOI":"10.1093\/neuonc\/nou089"},{"key":"e_1_3_1_27_2","doi-asserted-by":"crossref","unstructured":"Glantz MJ Cole BF Glantz LK et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998; 82 (4): 733\u2013739. doi:10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z.","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z"},{"key":"e_1_3_1_28_2","unstructured":"Nabors L Ammirati M Bierman P et al. NCCN clinical practice guidelines in oncology: central nervous system cancers (version 2.2013). www.nccn.org\/professionals\/physician_gls\/pdf\/cns.pdf. Accessed February 5 2015."},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Nayak L Abrey LE Iwamoto FM. Intracranial dural metastases. Cancer 2009; 115 (9): 1947\u20131953. doi:10.1002\/cncr.24203.","DOI":"10.1002\/cncr.24203"},{"key":"e_1_3_1_30_2","doi-asserted-by":"crossref","unstructured":"Chamberlain MC. Neoplastic meningitis and metastatic epidural spinal cord compression. Hematol Oncol Clin North Am 2012; 26 (4): 917\u2013931. doi:10.1016\/j.hoc.2012.04.004.","DOI":"10.1016\/j.hoc.2012.04.004"},{"key":"e_1_3_1_31_2","doi-asserted-by":"crossref","unstructured":"Patchell RA Tibbs PA Regine WF et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366 (9486): 643\u2013648. doi:10.1016\/S0140-6736(05)66954-1.","DOI":"10.1016\/S0140-6736(05)66954-1"},{"key":"e_1_3_1_32_2","doi-asserted-by":"crossref","unstructured":"Vecht CJ Haaxma-Reiche H van Putten WL et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989; 39 (9): 1255\u20131257. doi:10.1212\/WNL.39.9.1255.","DOI":"10.1212\/WNL.39.9.1255"},{"key":"e_1_3_1_34_2","doi-asserted-by":"crossref","unstructured":"Sung WS Sung MJ Chan JH et al. Intramedullary spinal cord metastases: a 20-year institutional experience with a comprehensive literature review. World Neurosurg 2013; 79 (3\u20134): 576\u2013584. doi:10.1016\/j.wneu.2012.04.005.","DOI":"10.1016\/j.wneu.2012.04.005"},{"key":"e_1_3_1_35_2","doi-asserted-by":"crossref","unstructured":"Rykken JB Diehn FE Hunt CH et al. Intramedullary spinal cord metastases: MRI and relevant clinical features from a 13-year institutional case series. AJNR Am J Neuroradiol 2013; 34 (10): 2043\u20132049. doi:10.3174\/ajnr.A3526.","DOI":"10.3174\/ajnr.A3526"},{"key":"e_1_3_1_36_2","doi-asserted-by":"crossref","unstructured":"Antoine JC Camdessanche JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007; 6 (1): 75\u201386. doi:10.1016\/S1474-4422(06)70679-2.","DOI":"10.1016\/S1474-4422(06)70679-2"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","unstructured":"Jaeckle KA. Neurologic manifestations of neoplastic and radiation-induced plexopathies. Semin Neurol 2010; 30 (3): 254\u2013262. doi:10.1055\/s-2004-861533.","DOI":"10.1055\/s-0030-1255219"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1212\/01.CON.0000464178.81957.18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:59:59Z","timestamp":1752155999000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/01.CON.0000464178.81957.18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1212\/01.CON.0000464178.81957.18"],"URL":"https:\/\/doi.org\/10.1212\/01.con.0000464178.81957.18","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4]]}}}